Jiangsu Hengrui
Tracked across 4 events · 51 articles · First seen Apr 22, 2026 · Last active Aug 12, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Jiangsu Hengrui reported strong Q1 2026 results with significant revenue and net profit growth, driven by innovative drugs and successful business development, including the Nasdaq-100 listing of Kailera Therapeutics.
Apr 22, 2026 · 6 articles
Tech
Impact: Jiangsu Hengrui presented over 90 studies at the ASCO Annual Meeting, showcasing its extensive oncology pipeline and innovative therapies, which could positively impact its market position and future drug approvals.
May 25, 2026 · 33 articles
Business
Impact: Struggling to recruit internationally experienced staff for global clinical trials and commercialization, which may slow overseas expansion.
Jul 15, 2026 · 6 articles
Business
Bicara Therapeutics, an AI-driven drug discovery company based in Chengdu, China, announced the successful closing of an oversubscribed Series A financing round, raising nearly $30 million. The round was co-led by Legend Holdings and Shanghai…
Impact: Jiangsu Hengrui is mentioned as a former employer of Beyang's team, adding industry experience but not directly impacted.
Jul 20, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Jiangsu Hengrui live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard